These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 14508145)

  • 21. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Calcium sensitization as new principle of inotropic therapy in end-stage heart failure?
    Zimmermann N; Boknik P; Gams E; Herzig JW; Neumann J; Scholz H
    Eur J Cardiothorac Surg; 1998 Jul; 14(1):70-5. PubMed ID: 9726618
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levosimendan, a new inotropic and vasodilator agent.
    Toller WG; Stranz C
    Anesthesiology; 2006 Mar; 104(3):556-69. PubMed ID: 16508404
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium sensitizer agents: a new class of inotropic agents in the treatment of decompensated heart failure.
    Perrone SV; Kaplinsky EJ
    Int J Cardiol; 2005 Sep; 103(3):248-55. PubMed ID: 16098385
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Levosimendan in cardiology and intensive care medicine].
    Delle Karth G; Heinz G
    Wien Klin Wochenschr; 2004 Jan; 116(1-2):6-14. PubMed ID: 15030117
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular effects of the calcium sensitizer, levosimendan, in heart failure induced by rapid pacing in the presence of aortic constriction.
    Udvary E; Papp JG; Végh A
    Br J Pharmacol; 1995 Feb; 114(3):656-61. PubMed ID: 7735692
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The utility of levosimendan in the treatment of heart failure.
    Lehtonen L; Põder P
    Ann Med; 2007; 39(1):2-17. PubMed ID: 17364447
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Levosimendan--an alternative to conventional inotropic treatment of patients with acute heart failure?].
    Rasmussen T; Schmidt H
    Ugeskr Laeger; 2006 Jan; 168(3):261-5. PubMed ID: 16430807
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacotherapeutic approaches for decompensated heart failure: a role for the calcium sensitiser, levosimendan?
    Greenberg B; Borghi C; Perrone S
    Eur J Heart Fail; 2003 Jan; 5(1):13-21. PubMed ID: 12559210
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Levosimendan: a review of its use in the management of acute decompensated heart failure.
    Innes CA; Wagstaff AJ
    Drugs; 2003; 63(23):2651-71. PubMed ID: 14636085
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levosimendan: a parenteral calcium-sensitising drug with additional vasodilatory properties.
    Lehtonen LA
    Expert Opin Investig Drugs; 2001 May; 10(5):955-70. PubMed ID: 11322869
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Levosimendan: a new era for inodilator therapy for heart failure?
    Cleland JG; McGowan J
    Curr Opin Cardiol; 2002 May; 17(3):257-65. PubMed ID: 12015475
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Levosimendan and dobutamine have a similar profile for potential risk for cardiac arrhythmias during 24-hour infusion in patients with acute decompensated heart failure].
    Tek M; Cavuşoğlu Y; Demirüstü C; Birdane A; Ünalır A; Görenek B; Göktekin Ö; Ata N
    Turk Kardiyol Dern Ars; 2010 Jul; 38(5):334-40. PubMed ID: 21200103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inoprotection: the perioperative role of levosimendan.
    Soeding PE; Royse CF; Wright CE; Royse AG; Angus JA
    Anaesth Intensive Care; 2007 Dec; 35(6):845-62. PubMed ID: 18084975
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pharmacology of levosimendan: inotropic, vasodilatory and cardioprotective effects.
    Pathak A; Lebrin M; Vaccaro A; Senard JM; Despas F
    J Clin Pharm Ther; 2013 Oct; 38(5):341-9. PubMed ID: 23594161
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Levosimendan versus dobutamine in critically ill patients: a meta-analysis of randomized controlled trials.
    Huang X; Lei S; Zhu MF; Jiang RL; Huang LQ; Xia GL; Zhi YH
    J Zhejiang Univ Sci B; 2013 May; 14(5):400-15. PubMed ID: 23645177
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of levosimendan on E/E' ratio in patients with ischemic heart failure.
    Duygu H; Ozerkan F; Nalbantgil S; Zoghi M; Akilli A; Akin M; Nazli C; Ergene O
    Int J Cardiol; 2008 Jan; 123(2):201-3. PubMed ID: 17316845
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Intravenous levosimendan treatment is cost-effective compared with dobutamine in severe low-output heart failure: an analysis based on the international LIDO trial.
    Cleland JG; Takala A; Apajasalo M; Zethraeus N; Kobelt G
    Eur J Heart Fail; 2003 Jan; 5(1):101-8. PubMed ID: 12559222
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Levosimendan in two neonates with ischemic heart failure and pulmonary hypertension.
    De Carolis MP; Piastra M; Bersani I; Pardeo M; Stival E; Tempera A; Romagnoli C; Conti G; De Rosa G
    Neonatology; 2012; 101(3):201-5. PubMed ID: 22067520
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A promising new inotrope: levosimendan.
    Fotbolcu H; Duman D
    Anadolu Kardiyol Derg; 2010 Apr; 10(2):176-82. PubMed ID: 20382619
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.